ExodusPoint Capital Management LP Purchases Shares of 197,800 Bausch Health Companies Inc. (NYSE:BHC)

ExodusPoint Capital Management LP acquired a new position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 197,800 shares of the company's stock, valued at approximately $1,594,000. ExodusPoint Capital Management LP owned approximately 0.05% of Bausch Health Companies as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Tobam raised its holdings in Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after purchasing an additional 1,422 shares during the last quarter. American Century Companies Inc. raised its position in shares of Bausch Health Companies by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock worth $220,000 after purchasing an additional 2,600 shares during the last quarter. Blair William & Co. IL raised its position in shares of Bausch Health Companies by 3.2% during the 4th quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock worth $683,000 after purchasing an additional 2,622 shares during the last quarter. Sanders Morris Harris LLC grew its holdings in Bausch Health Companies by 16.0% during the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock valued at $234,000 after buying an additional 4,000 shares during the last quarter. Finally, Kendall Capital Management grew its holdings in Bausch Health Companies by 43.4% during the 4th quarter. Kendall Capital Management now owns 17,995 shares of the company's stock valued at $145,000 after buying an additional 5,445 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several brokerages have recently issued reports on BHC. Jefferies Financial Group restated a "hold" rating and issued a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada reduced their target price on shares of Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Bausch Health Companies currently has an average rating of "Hold" and an average target price of $7.17.

Bausch Health Companies Trading Down 1.0 %

Shares of NYSE BHC traded down $0.05 on Tuesday, reaching $4.30. 589,604 shares of the company traded hands, compared to its average volume of 2,679,197. The stock has a market capitalization of $1.58 billion, a PE ratio of -35.79, a P/E/G ratio of 0.37 and a beta of 0.43. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The company has a 50 day moving average of $6.47 and a 200 day moving average of $7.51.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The company had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. As a group, research analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.